Noom is putting labs in the loop.
What’s happening: The clinically integrated behavior change platform launched at-home biomarker testing kits to track efficacy of its metabolic health and longevity programs.
DIY. Tapping Tasso+ microneedle blood collection devices, Noom will decode 17 biomarkers across cardiometabolic, hormonal, inflammatory, and nutritional domains for members, providing insights into lifestyle and medical weight loss, with results available in the free version of its app.
Every step. Analyzing recent Tasso-drawn data from its microdosed GLP-1 longevity program, Noom found the majority of its “healthy” users were above baseline — 70% had elevated LDL cholesterol, while over a third were at risk for pre-diabetes despite a normal BMI.
A powerful feedback layer for more than just clinical users, Noom will now plug frictionless bloodwork into an ecosystem of wearables-integrated AI coaching, drug “catalysts,” and pharmacy fulfillment, providing motivation and encouraging medication adherence with outcomes they can see.
Punchline: Moving its entry point from correction to detection, Noom’s targeting healthy habits, smarter decisions, and high engagement.
